Elevated doublecortin-like kinase 1 serum levels revert to baseline after therapy in early stage esophageal adenocarcinoma.
Cancer stem cell
DCLK1
Doublecortin-like kinase 1
ELISA
Esophageal adenocarcinoma
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
12
2018
accepted:
27
02
2019
entrez:
23
3
2019
pubmed:
23
3
2019
medline:
23
3
2019
Statut:
epublish
Résumé
Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) incidence has been increasing in the United States for greater than 30 years. For the majority of EAC patients, treatment is limited and prognosis poor. Doublecortin like kinase-1 (DCLK1) is a cancer stem cell marker with elevated expression in BE patients with high grade dysplasia and/or EAC. This prospective cohort study was designed to compare serum DCLK1 levels before and after EAC treatment with endoscopic mucosal resection (EMR) and/or radio-frequency ablation (RFA). Barrett's esophagus patients with low or high-grade dysplasia ( Serum DCLK1 levels were increased by > 50% in Barrett's Esophagus ( EAC treatment results in significantly decreased serum DCLK1 levels, suggesting that DCLK1 may be useful as a non-invasive disease regression biomarker following treatment. Biomarkers for EAC therapeutic response have been poorly studied and no reliable marker has been discovered thus far. These results demonstrate that DCLK1 may have potential as a circulating biomarker of the response to therapy in EAC, which could be used to improve patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) incidence has been increasing in the United States for greater than 30 years. For the majority of EAC patients, treatment is limited and prognosis poor. Doublecortin like kinase-1 (DCLK1) is a cancer stem cell marker with elevated expression in BE patients with high grade dysplasia and/or EAC. This prospective cohort study was designed to compare serum DCLK1 levels before and after EAC treatment with endoscopic mucosal resection (EMR) and/or radio-frequency ablation (RFA).
METHODS
METHODS
Barrett's esophagus patients with low or high-grade dysplasia (
RESULTS
RESULTS
Serum DCLK1 levels were increased by > 50% in Barrett's Esophagus (
CONCLUSIONS
CONCLUSIONS
EAC treatment results in significantly decreased serum DCLK1 levels, suggesting that DCLK1 may be useful as a non-invasive disease regression biomarker following treatment.
IMPACT
CONCLUSIONS
Biomarkers for EAC therapeutic response have been poorly studied and no reliable marker has been discovered thus far. These results demonstrate that DCLK1 may have potential as a circulating biomarker of the response to therapy in EAC, which could be used to improve patient outcomes.
Identifiants
pubmed: 30899515
doi: 10.1186/s40364-019-0157-z
pii: 157
pmc: PMC6408757
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Déclaration de conflit d'intérêts
All patients provided informed consent and samples were deidentified. The University of Oklahoma Health Sciences Center Institutional Review Board approved the study.Not applicable.NW and CWH have ownership interests in COARE Holdings Inc.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Gastroenterology. 2000 Apr;118(4):670-7
pubmed: 10734018
N Engl J Med. 2002 Mar 14;346(11):836-42
pubmed: 11893796
J Natl Cancer Inst. 2005 Jan 19;97(2):142-6
pubmed: 15657344
Gut. 2007 Nov;56(11):1625-34
pubmed: 17938435
Gut. 2008 Sep;57(9):1200-6
pubmed: 18460553
Clin Gastroenterol Hepatol. 2010 Jan;8(1):23-9
pubmed: 19602454
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Dig Dis Sci. 2015 Feb;60(2):509-13
pubmed: 25283374
Am J Physiol Gastrointest Liver Physiol. 2017 Oct 1;313(4):G285-G299
pubmed: 28684459
Gastroenterology. 1993 Jul;105(1):119-29
pubmed: 8514029
Am J Gastroenterol. 1997 Feb;92(2):212-5
pubmed: 9040193
Gastroenterology. 1997 May;112(5):1448-56
pubmed: 9136821